Clinical Trial Update: Clinical Trial to Evaluate Safety, Tolerability and Efficacy of NFX88 in SCI [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, and efficacy of NFX88 in neuropathic pain associated with spinal cord injuries has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuropathic Pain
• Spinal Cord Injury

Drugs mentioned

• NFX88

Snippet

Sponsor: Neurofix S.L. | Conditions: Neuropathic Pain, Spinal Cord Injuries | Phase 2 | Status: COMPLETED